Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
European Society of Cardiology
Biotech
Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts
Patients' disease stage, transthyretin knockdown levels and trial design have become focal points in debates around silencer-stabilizer combos.
Fraiser Kansteiner
,
Darren Incorvaia
Sep 1, 2026 1:55pm
AstraZeneca's heart failure drug shows promise in ph. 2 trial
Aug 31, 2026 11:13am
AI could spot heart disease in breast cancer mammograms
Mar 9, 2026 2:25pm
Cytokinetics’ ph. 3 cardio win sends stock soaring
Sep 2, 2025 2:05pm
At ESC 2025, researchers call for earlier, simpler TAVR
Aug 29, 2025 1:00pm
Philips, Siemens Healthineers push AI for heart ultrasound scans
Aug 29, 2023 1:13pm
